Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Charles River to Buy WuXi PharmaTech for $1.6B

April 26, 2010 5:44 am | News | Comments

Medical research equipment and services company Charles River Laboratories International Inc. plans to buy WuXi PharmaTech, a Chinese pharmaceutical outsourcing company, for $1.6 billion.


MannKind Wins Two Facility of the Year Awards

April 23, 2010 8:02 am | News | Comments

MannKind Corporation announced that its commercial manufacturing facility, custom-built for the production of its proprietary insulin therapy, has been awarded two Facility of the Year 2010 category awards for process innovation and equipment innovation.


Cresset Appoints Rob Scoffin CEO

April 23, 2010 7:59 am | News | Comments

Cresset has announce the appointment of Dr Rob Scoffin as Chief Executive Officer of Cresset Group. Rob replaces Beatrice Leigh, who will now become non-executive Chairman of the Board.


LMU Research Could Lead to New Antiviral Therapies

April 23, 2010 7:51 am | News | Comments

Viruses have evolved a broad range of strategies that enable them to evade the immune systems of their hosts. A team of researchers has been studying a novel, recently discovered mechanism that pathogenic viruses exploit for this purpose.


Psychedelic Drugs Lessen Depression and Anxiety

April 23, 2010 7:47 am | by Malcolm Ritter | News | Comments

A New York University study of psychedelic drugs is among a handful now going on in the United States and elsewhere with drugs like LSD, MDMA (Ecstasy) and psilocybin, the main ingredient of "magic mushrooms."


TransKingdom RNA-interference (tkRNAi)

April 23, 2010 7:32 am | Articles | Comments

RNA interference (RNAi) is a recently described biologic phenomenon that allows suppression of targeted genes in a highly specific and efficient manner and is being developed as a therapeutic modality with significant medical potential.


Seroquel Recommended By EMA for Depression

April 23, 2010 7:15 am | News | Comments

Pharmaceutical company AstraZeneca PLC says its schizophrenia drug Seroquel XR has been recommended by European regulators as an add-on treatment for depression.


Genentech Submits sBLA to FDA

April 23, 2010 7:09 am | News | Comments

Genentech, Inc. has submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for Herceptin plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach.


EMA Recommends Approval of Daxas

April 23, 2010 7:03 am | News | Comments

Daxas is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that has been developed by Nycomed for the treatment of COPD.


Baxter Shares Plummet On Profit Outlook

April 23, 2010 6:55 am | by Damian Troise | News | Comments

Shares of Baxter International plunged after the company cut its full-year profit outlook on slower-than-expected sales of plasma-based drugs and charges related to health care reform.


Pfizer Shareholders Reject Removal of Executive Stock Options

April 23, 2010 6:39 am | by Linda A. Johnson | News | Comments

Pfizer Inc. shareholders overwhelmingly rejected a proposal to stop giving top executives stock options, but the company's CEO still took some heat over that issue and Pfizer's low stock price and reduced profit forecast.


EU Approves Novartis Hypertension Drug for Children

April 23, 2010 6:34 am | News | Comments

Pharmaceutical maker Novartis AG said the European Union has approved its best-selling hypertension drug Diovan for treatment of children aged 6-18.


Pfizer Cuts Sutent Trial Short

April 23, 2010 6:28 am | News | Comments

Pfizer Inc. said it stopped a late-stage clinical study of its drug Sutent as a treatment for liver cancer.


FDA Panel Roundly Rejects Acurox

April 23, 2010 6:25 am | by Matthew Perrone | News | Comments

Federal health experts said overwhelmingly that an experimental painkiller designed to discourage misuse is not effective enough to warrant approval.



April 23, 2010 6:06 am | Drug Discovery & Development | Product Releases | Comments

Spark Holland’s ultra high pressure pump, the SPH1240, provides 18,000 psi for the entire range of UHPLC analytical flow rates. Accurate flow delivery combined with dedicated adjustment of mixing volume and compressibility compensation guarantee a rapid and reproducible gradient.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.